Please note that Naglazyme and Vimzim revenues vary on a quarterly basis, primarily due to the timing of central government orders from some countries, mainly Brazil.New patient growth is likely to have driven sales of BioMarinâ€™s newest drugs, Brineura and Palynziq injection higher in the fourth quarter.